Amneal ‘Hyper Focused’ On New Launches
As Generics Business Exceeds Expectations In The First Quarter
Aiming to “aggressively expand sales,” Amneal has announced that it will be launching 15 new generics by August 2021. Amneal’s generics business has also reported growth beyond its set targets for the first quarter of 2020.
You may also be interested in...
Amneal Lines Up Launches As It Builds Out Biosimilars Business
Fresh from introducing its first biosimilar in the US, Amneal expects two additional biosimilars to launch in the next couple of months as well as several further generics by year end. The firm also has its eye on future biosimilars opportunities where it can be early to market.
Amneal Launches US Rival To Butrans
Following approval by the FDA, Amneal has launched a generic version of the Butrans buprenorphine transdermal system, immediately initiating commercialization activities across all strengths.
Sun, Accord, Amneal And Apotex Donate Hydroxychloroquine
Major generics companies have donated hydroxychloroquine sulfate doses for research and treatment of coronavirus. Companies are also donating hand sanitizer and personal protective equipment and are preparing to ramp up manufacturing and production.